AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3290034
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravenous glucagon (50 patients)
Trial: 7679164
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg, three times daily for 3 days)
Trial: 28468607
Drug: Group LIA
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group LIA (Local Infiltration Analgesia) with 30 mL saline, ropivacaine 2 mg/mL (300 mg), ketorolac 30 mg, adrenaline 0.5 mg
Trial: 28468607
Drug: Group FNB
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group FNB (Femoral Nerve Block) with 30 mL ropivacaine 7.5 mg/mL (225 mg) and 151.5 mL saline
Trial: 26073387
Drug: ETC-1002 60
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 60 mg daily (increased to 120 mg, 180 mg, and 240 mg at 2-week intervals)
Trial: 24173676
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml 0.5% levobupivacaine plus 4 mg dexamethasone (group 1)
Trial: 24173676
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml 0.5% levobupivacaine plus 1 ml saline (group 2)
Trial: 22679695
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (0.3 mg) or bevacizumab (0.625 mg/0.025 ml) with conventional diode laser photocoagulation (Group A)
Trial: 22679695
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy combined with cryotherapy (Group B)
Trial: 19041224
Drug: Coenzyme Q(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10) (50 mg/d), vitamin E (50 mg/d), and selenium (48 mug/d)
Trial: 8633396
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of the International Prostate Symptom Score (IPSS)
Trial: 8633396
Drug: Physician administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician administration of the International Prostate Symptom Score (IPSS)
Trial: 19915217
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (2000 mg per day)
Trial: 19915217
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg per day)
Trial: 9253326
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE; 250 mg, i.m., every 21 days)
Trial: 9253326
Drug: Single s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single s.c. implantation of 1200 mg crystalline testosterone (TPEL)
Trial: 31225647
Drug: BoNT‐A plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A plus occupational therapy
Trial: 23787544
Drug: Paricalcitol 2
RxNorm normalized name: PARICALCITOL 2MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol 2 μg/day
Trial: 16948806
Drug: Tapering down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering down omeprazole for three weeks
Trial: 16948806
Drug: Constant dosage
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dosage of omeprazole for three weeks
Trial: 16948806
Drug: Overall discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall discontinuation of PPIs
Trial: 10899492
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA), 50 mg/d for 3 months
Trial: 8177098
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (20 micrograms ethinyl estradiol and 150 micrograms desogestrel) for 6 months
Trial: 3653128
Drug: Oestrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen therapy (polyestradiol phosphate 80 mg i.m. per month + 150 micrograms ethinylestradiol p.o. per day)
Trial: 27940956
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg subcutaneously before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Trial: 26575873
Drug: Aminophylline 1
RxNorm normalized name: aminophylline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 1 mg/kg, once every 8 hours
Trial: 26575873
Drug: Aminophylline 2
RxNorm normalized name: aminophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 2 mg/kg, once every 8 hours
Trial: 21504340
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of oral micronized progesterone capsules (Utrogestan 3 x 100 mg) and vaginal progesterone gel (Crinone 8%, 90 mg daily)
Trial: 21504340
Drug: Progesterone monotherapy
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone monotherapy (vaginal progesterone gel, Crinone 8%, 90 mg daily)
Trial: 21504340
Drug: Progesterone monotherapy
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone monotherapy
Trial: 18425621
Drug: Thalidomide (THL)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide (THL) in combination with riluzole
Trial: 16495259
Drug: Artesunate suppositories
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate suppositories (8 to 16 mg/kg at 0 and 12 h, then daily)
Trial: 16495259
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (3.2 mg/kg at 0 h, then 1.6 mg/kg daily)
Trial: 2317442
Drug: Inderal LA
RxNorm normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inderal LA 80 mg
Trial: 2317442
Drug: Inderal LA
RxNorm normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inderal LA 160 mg
Trial: 2317442
Drug: Inderal LA
RxNorm normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inderal LA 320 mg
Trial: 31137994
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with LP Nd:YAG laser and 10% KOH application
Trial: 31137994
Drug: LP Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP Nd:YAG laser therapy only
Trial: 25869983
Drug: Modified osteotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified osteotomy design (angled oblique buccal bone cut)
Trial: 10648268
Drug: Vitamin cocktail
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin cocktail containing 272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopheryl acetate, and 400 microg folic acid
Trial: 9144686
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months)
Trial: 9144686
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with oral cyclophosphamide (100 mg/m2/d days 1 through 14), intravenous methotrexate (40 mg/m2 days 1 and 8), intravenous 5-fluorouracil (600 mg/m2 days 1 and 8), and oral prednisolone (40 mg/m2/d days 1 through 14) for six cycles (6 months)
Trial: 8129554
Drug: Hydroquinidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinidine (600 mg per 24 hours)
Trial: 8129554
Drug: Quinidine (1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (1100 mg)
Trial: 24702733
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with metformin
Trial: 24702733
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with rosiglitazone
Trial: 24702733
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with intensive lifestyle intervention
Trial: 20446889
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D intake (average daily intake 144.8 IU, SD 84.6)
Trial: 20446889
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake (average daily intake 966.4 mg, SD 273.7)
Trial: 18611063
Drug: Intravenous lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lanthanum chloride
Trial: 18611063
Drug: Oral lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lanthanum carbonate (3000 mg/day)
Trial: 18611063
Drug: Oral lanthanum
RxNorm normalized name: lanthanum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lanthanum carbonate
Trial: 12851624
Drug: AMP579 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP579 (60 mcg/kg)
Trial: 12851624
Drug: AMP579 (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP579 (other doses)
Trial: 12851624
Drug: AMP579 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP579 (all doses)
Trial: 11601221
Drug: Antilymphocyte globulin
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte globulin (ALG) combined with cyclosporine A (CsA) - Intensive immunosuppressive therapy (IIST)
Trial: 11601221
Drug: Antilymphocyte globulin
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte globulin (ALG) alone - Non-intensive immunosuppressive therapy (NIIST)
Trial: 8678273
Drug: Pressure-controlled mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-controlled mechanical ventilation with PEEP and permissive hypercapnia, body position changes, inhalation of nitric oxide.
Trial: 8678273
Drug: Traditional standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional standard treatment (not specified in detail).
Trial: 1411294
Drug: Bismuth compound
RxNorm normalized name: Bismuth compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth compound (120 mg four times daily)
Trial: 24680768
Drug: Tacrolimus administered
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus administered via site-specific radiolabeled delivery capsule (1 mg in 2 mg/mL solution)
Trial: 24680768
Drug: Tacrolimus administered
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus administered via site-specific radiolabeled delivery capsule
Trial: 20199989
Drug: Control (antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antiretroviral treatment only)
Trial: 18279690
Drug: Three gels
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three gels containing different doses of N-9
Trial: 18279690
Drug: Three different
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three different formulations containing the same dose of N-9
Trial: 18279690
Drug: Different formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different formulations and doses of spermicides containing N-9
Trial: 16167911
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of levobupivacaine
Trial: 16167911
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of racemic bupivacaine
Trial: 8904258
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg lidocaine (LD)
Trial: 8904258
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg meperidine (MP)
Trial: 8904258
Drug: 25 mu
RxNorm normalized name: OCTINOXATE 0.07 g in 1 g / ZINC OXIDE 0.084 g in 1 g TOPICAL CREAM [CY BB Facial Hidratante con Color FPS 25 Multibeneficios]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mu g fentanyl (FN)
Trial: 6280796
Drug: New designed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New designed intermittent polychemotherapy-schedule (alternating cyclophosphamid + CCNU + MTX, then cyclophosphamid + adriamycin + vincristin, then ifosfamid + VP‐16) followed by radiation therapy
Trial: 23206459
Drug: Oral prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prolonged-release oxycodone/naloxone (OXN PR)
Trial: 11857049
Drug: Flaxseed supplementation
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed supplementation (1.3 g/100 g ground flaxseed and 5 g/100 g flaxseed oil)
Trial: 10439881
Drug: Low-dose glucose-insulin-potassium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucose-insulin-potassium (GIK)
Trial: 25199856
Drug: Dietary NO3(‐)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary NO3(‐) intake (140 mL of concentrated beetroot juice containing 11.2 mmol of NO3(‐))
Trial: 25199856
Drug: Placebo (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (140 mL of beetroot juice devoid of NO3(‐))
Trial: 23726325
Drug: Oscillating-rotating electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillating-rotating electric toothbrush with a specially designed orthodontic brush head (Oral-B Triumph, OD17)
Trial: 17146025
Drug: Health plan-based
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Health plan-based lifestyle intervention (bimonthly group meetings, quarterly coaching telephone calls, and weekly self-monitoring)
Trial: 12750437
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir administration
Trial: 12750437
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir administration
Trial: 3909500
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 300 mg daily for 2 weeks
Trial: 3909500
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 600 mg daily for 2 weeks
Trial: 3909500
Drug: Atherogenic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atherogenic diet with 100 mg vitamin E daily
Trial: 29365382
Drug: Systemic glucocorticoids
RxNorm normalized name: Glucocorticoids, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic glucocorticoids combined with inhaled steroid (Budesonide suspension 1.0 mg for inhalation, oxygen-driven atomizing inhalation, every 30 minutes, 2 times in a row, then every 12 hours)
Trial: 29365382
Drug: Systemic glucocorticoids
RxNorm normalized name: Glucocorticoids, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic glucocorticoids (Dexamethasone injection 0.3‐0.5 mg/kg for 1‐3 days)
Trial: 25359002
Drug: Tornado program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tornado program (accelerated-track diagnosis and treatment planning, psychoeducation, pharmacological treatment by primary care physicians)
Trial: 22616062
Drug: Ceramic material
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramic material titanium niobium oxynitride ([Ti,Nb]ON) with plasma‐chemical oxidation treatment
Trial: 20736206
Drug: Overlapping drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overlapping drug-eluting stents (DES)
Trial: 11986913
Drug: Regular nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular nimodipine 30 mg every 6 h
Trial: 11986913
Drug: Nimodipine AP
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine AP 120 mg every 24 h
Trial: 7486485
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (eicosapentaenoic and docosahexaenoic acids), 4 g/d
Trial: 7486485
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil placebo, 4 g/d
Trial: 453056
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of about 280 mg N/kg per day (mixed animal and plant protein sources) for 8 weeks
Trial: 453056
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of about 90 mg N/kg per day (egg protein) for 11 weeks
Trial: 31605197
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g inulin plus 10 g resistant maltodextrin
Trial: 31605197
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g placebo supplementation
Trial: 31290566
Drug: Regorafenib pharmacokinetics
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib pharmacokinetics in major gastrectomy
Trial: 31290566
Drug: Regorafenib pharmacokinetics
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib pharmacokinetics in no/nonsignificant gastrectomy
Trial: 27508295
Drug: Serum IGF-1
RxNorm normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Serum IGF-1 levels in SGA infants (27.6 ± 17.7 ng/ml)
Trial: 25172025
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (tDCS and sertraline)
Trial: 24136883
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without bevacizumab
Trial: 18951992
Drug: Liposomal amphotericin-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin-B (L‐AmB)
Trial: 2262461
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 250 mg oral doses
Trial: 434096
Drug: Sucrose gradient
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose gradient purified vaccine
Trial: 434096
Drug: Genetron purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetron purified vaccine
Trial: 26081597
Drug: 5-hydroxytryptamine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment
Trial: 23404064
Drug: Bromocriptine (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (dopamine receptor agonist)
Trial: 21367927
Drug: TPD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPD 20 μg daily
Trial: 20396750
Drug: Afobazole (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afobazole (30-60 mg/day for 1 month)
Trial: 11331253
Drug: phVEGF‐2 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phVEGF‐2 (200 microgram total dose, 6 injections of 6.0 mL)
Trial: 7993958
Drug: d-amphetamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.5 mg/kg orally)
Trial: 3053312
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid regimen (1 tablet q.i.d.; acid-neutralizing capacity, 120 mmol/day)
Trial: 30373502
Drug: Mobility Feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobility Feedback Device (MFD) used weekly for 6 months
Trial: 29267990
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral electroconvulsive therapy
Trial: 29267990
Drug: Algorithm-based pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-based pharmacologic treatment
Trial: 26432772
Drug: Chlorella supplement
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplement (4 tablets, total chlorophyll ≈8.3 mg/tablet, three times a day for 2 weeks)
Trial: 26432772
Drug: Chlorella supplement
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplement
Trial: 19034737
Drug: Naltrexone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone at 150 mg/day
Trial: 11207640
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) at 3 IU/(m(2) body surface.day)